Glaukos Corp（股票代码：GKOS）周四盘前股价大跌8.74%，引起投资者广泛关注。这一显著跌幅似乎与多家知名投资银行下调该公司目标股价有关。
根据最新消息，摩根大通大幅下调了Glaukos的目标价，从此前的160美元骤降至100美元，降幅高达37.5%。与此同时，Truist Securities也下调了其目标价，从140美元下调至135美元。这些目标价的显著下调反映了分析师对公司未来表现的担忧，可能是导致股价大跌的主要原因。
作为一家专注于开发和商业化用于治疗青光眼的创新技术的医疗器械公司，Glaukos的股价表现一直受到市场密切关注。分析师目标价的大幅下调可能意味着对公司近期财务业绩或未来增长前景的看法发生了变化。投资者应密切关注公司接下来的公告和财报，以更好地理解这次股价调整背后的具体原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.